{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T03:27:13Z","timestamp":1777865233568,"version":"3.51.4"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,2,10]],"date-time":"2021-02-10T00:00:00Z","timestamp":1612915200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004955","name":"\u00d6sterreichische Forschungsf\u00f6rderungsgesellschaft","doi-asserted-by":"publisher","award":["858017"],"award-info":[{"award-number":["858017"]}],"id":[{"id":"10.13039\/501100004955","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.ejmech.2021.113285","type":"journal-article","created":{"date-parts":[[2021,2,18]],"date-time":"2021-02-18T17:53:56Z","timestamp":1613670836000},"page":"113285","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Tackling resistance in chronic myeloid leukemia: Novel cell death modulators with improved efficacy"],"prefix":"10.1016","volume":"216","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7536-1906","authenticated-orcid":false,"given":"Anna M.","family":"Schoepf","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2391-6954","authenticated-orcid":false,"given":"Stefan","family":"Salcher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petra","family":"Obexer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald","family":"Gust","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2021.113285_bib1","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1016\/j.drudis.2019.05.007","article-title":"Current outlook on drug resistance in chronic myeloid leukemia (CML) and potential therapeutic options","volume":"24","author":"Meenakshi Sundaram","year":"2019","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2021.113285_bib2","doi-asserted-by":"crossref","first-page":"939","DOI":"10.3389\/fonc.2019.00939","article-title":"BCR-ABL independent mechanisms of resistance in chronic myeloid leukemia","volume":"9","author":"Loscocco","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejmech.2021.113285_bib3","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/emmm.201000062","article-title":"Stat5 is indispensable for the maintenance of bcr\/abl-positive leukaemia","volume":"2","author":"Hoelbl","year":"2010","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.ejmech.2021.113285_bib4","doi-asserted-by":"crossref","first-page":"9564","DOI":"10.18632\/oncotarget.2465","article-title":"Inhibition of STAT5: a therapeutic option in BCR-ABL1-driven leukemia","volume":"5","author":"Berger","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2021.113285_bib5","doi-asserted-by":"crossref","first-page":"843","DOI":"10.3324\/haematol.2016.153270","article-title":"Increased peroxisome proliferator-activated receptor \u03b3 activity reduces imatinib uptake and efficacy in chronic myeloid leukemia mononuclear cells","volume":"102","author":"Wang","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.ejmech.2021.113285_bib6","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/cbdd.12737","article-title":"Peroxisome proliferator-activated receptor ligands and their role in chronic myeloid leukemia: therapeutic strategies","volume":"88","author":"Yousefi","year":"2016","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.ejmech.2021.113285_bib7","doi-asserted-by":"crossref","DOI":"10.1177\/1010428317716501","article-title":"Balaglitazone reverses P-glycoprotein-mediated multidrug resistance via upregulation of PTEN in a PPAR\u03b3-dependent manner in leukemia cells","volume":"39","author":"Yousefi","year":"2017","journal-title":"Tumor Biol."},{"key":"10.1016\/j.ejmech.2021.113285_bib8","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/nature15248","article-title":"Erosion of the chronic myeloid leukaemia stem cell pool by PPAR\u03b3 agonists","volume":"525","author":"Prost","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2021.113285_bib9","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1002\/cncr.30490","article-title":"Pioglitazone together with imatinib in chronic myeloid leukemia: a proof of concept study","volume":"123","author":"Rousselot","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.ejmech.2021.113285_bib10","doi-asserted-by":"crossref","first-page":"e377","DOI":"10.1038\/bcj.2015.109","article-title":"PPAR\u03b3 ligands increase antileukemic activity of second- and third-generation tyrosine kinase inhibitors in chronic myeloid leukemia cells","volume":"6","author":"Glodkowska-Mrowka","year":"2016","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.ejmech.2021.113285_bib11","doi-asserted-by":"crossref","first-page":"111748","DOI":"10.1016\/j.ejmech.2019.111748","article-title":"Overcoming imatinib resistance in chronic myelogenous leukemia cells using non-cytotoxic cell death modulators","volume":"185","author":"Schoepf","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113285_bib12","doi-asserted-by":"crossref","first-page":"112258","DOI":"10.1016\/j.ejmech.2020.112258","article-title":"Identification and development of non-cytotoxic cell death modulators: impact of sartans and derivatives on PPAR\u03b3 activation and on growth of imatinib-resistant chronic myelogenous leukemia cells","volume":"195","author":"Schoepf","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113285_bib13","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1002\/cmdc.202000092","article-title":"Synthesis and characterization of telmisartan-derived cell death modulators to circumvent imatinib resistance in chronic myeloid leukemia","volume":"15","author":"Schoepf","year":"2020","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2021.113285_bib14","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1002\/cmdc.200800285","article-title":"Characterization of new PPAR\u03b3 agonists: analysis of telmisartan\u2019s structural components","volume":"4","author":"Goebel","year":"2009","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2021.113285_bib15","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.ejmech.2016.08.027","article-title":"New telmisartan-derived PPAR\u03b3 agonists: impact of the 3D-binding mode on the pharmacological profile","volume":"124","author":"Obermoser","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113285_bib16","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0022-1759(83)90303-4","article-title":"Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays","volume":"65","author":"Mosmann","year":"1983","journal-title":"J.\u00a0Immunol. Methods"},{"key":"10.1016\/j.ejmech.2021.113285_bib17","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-128265","article-title":"Pioglitazone did not affect PPAR-\u03b3, STAT5, HIF2\u03b1 and CITED2 gene expression in chronic myeloid leukemia patients with deep molecular response","volume":"134","author":"Lopes","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2021.113285_bib18","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1038\/s41375-017-0005-9","article-title":"Pharmacologic inhibition of STAT5 in acute myeloid leukemia","volume":"32","author":"Wingelhofer","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmech.2021.113285_bib19","doi-asserted-by":"crossref","first-page":"3409","DOI":"10.1182\/blood-2009-10-248211","article-title":"High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia","volume":"117","author":"Warsch","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2021.113285_bib20","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/cyto.a.10063","article-title":"Immunoreactivity of STAT5 phosphorylated on tyrosine as a cell-based measure of BCR\/ABL kinase activity","volume":"54","author":"Jacobberger","year":"2003","journal-title":"Cytometry"},{"key":"10.1016\/j.ejmech.2021.113285_bib21","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1124\/mol.61.1.7","article-title":"Diclofenac antagonizes peroxisome proliferator-activated receptor-gamma signaling","volume":"61","author":"Adamson","year":"2002","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ejmech.2021.113285_bib22","doi-asserted-by":"crossref","first-page":"6640","DOI":"10.1021\/bi0159581","article-title":"Functional consequences of cysteine modification in the ligand binding sites of peroxisome proliferator activated receptors by GW9662","volume":"41","author":"Leesnitzer","year":"2002","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2021.113285_bib23","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1158\/1535-7163.MCT-07-0397","article-title":"Doxorubicin activates FOXO3a to induce the expression of multidrug resistance gene ABCB1 (MDR1) in K562 leukemic cells","volume":"7","author":"Hui","year":"2008","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2021.113285_bib24","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s12943-017-0661-4","article-title":"C10ORF10\/DEPP-mediated ROS accumulation is a critical modulator of FOXO3-induced autophagy","volume":"16","author":"Salcher","year":"2017","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ejmech.2021.113285_bib25","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1002\/cmdc.201600417","article-title":"Targeting a targeted drug: an approach toward hypoxia-activatable tyrosine kinase inhibitor prodrugs","volume":"11","author":"Karnthaler-Benbakka","year":"2016","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2021.113285_bib26","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1016\/S0022-2275(20)32433-0","article-title":"Modulation of rat liver apolipoprotein gene expression and serum lipid levels by tetradecylthioacetic acid (TTA) via PPARalpha activation","volume":"40","author":"Raspe","year":"1999","journal-title":"J.\u00a0Lipid Res."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523421001343?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523421001343?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T06:00:33Z","timestamp":1777528833000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523421001343"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":26,"alternative-id":["S0223523421001343"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2021.113285","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tackling resistance in chronic myeloid leukemia: Novel cell death modulators with improved efficacy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2021.113285","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"113285"}}